Lenalidomide Stada (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, changing the complex’s substrate specificity. This leads to the degradation of transcription factors such as Ikaros and Aiolos, resulting in anti‑angiogenic effects, modulation of cytokine release, and direct anti‑tumor activity through apoptosis and inhibition of malignant cell proliferation.

The dosage of Lenalidomide Stada is individualized and must be determined by a qualified prescriber based on the specific indication, patient characteristics, renal function, and concomitant therapies. Healthcare professionals set the appropriate dose and schedule according to current clinical guidelines and patient response.

Lenalidomide is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy because of proven teratogenicity. Women of childbearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in breast milk and could harm the infant.

To order Lenalidomide Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide shares the same class (immunomodulatory imide drugs) as thalidomide and pomalidomide but generally offers a more favorable safety profile, especially regarding peripheral neuropathy. It provides stronger anti‑angiogenic and immunomodulatory effects, making it a preferred option for many patients with multiple myeloma and related disorders, though choice depends on individual clinical factors.

Store Lenalidomide Stada at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in the bathroom or near heat sources, and ensure the container is tightly closed when not in use.

Lenalidomide Stada is taken orally, usually with or without food, as directed by the prescribing physician. The tablets (or capsules, depending on the specific product) should be swallowed whole with a glass of water. Patients should follow the exact dosing schedule provided by their healthcare professional.

The most serious risks include severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, and the potential for venous thromboembolism. Additionally, there is a risk of secondary primary malignancies and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these events occur.

Lenalidomide Stada should not be used by pregnant women, individuals who are not using effective contraception, patients with known hypersensitivity to lenalidomide or any component of the formulation, and those with severe renal impairment without appropriate dose adjustment. Clinicians must also evaluate contraindications related to concurrent medications and comorbid conditions.